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Abstract
Background: Urinary tract infections are one of the most common reasons for prescribing antibiotics in primary
care. Current guidelines recommend fosfomycin, nitrofurantoin, or trimethoprim - sulfamethoxazol as empiric first
line antimicrobial agents in uncomplicated infections. However, there is evidence that the use of fluoroquinolones,
which are no longer recommended, is still inappropriate high. We determined antibiotic prescription patterns,
quality and factors affecting antibiotic prescriptions in urinary tract infections in primary care in Switzerland.
Methods: From June 2017 to August 2018, we conducted a cross-sectional study in patients suffering from a
urinary tract infection (UTI). Patient and general practitioners characteristics as well as antibiotic prescribing patterns
were analysed.
Results: Antibiotic prescribing patterns in 1.352 consecutively recruited patients, treated in 163 practices could be
analysed. In 950 (84.7%) patients with an uncomplicated UTI the prescriptions were according to current guidelines
and therefore rated as appropriate. Fluoroquinolones were prescribed in 13.8% and therefore rated as inappropriate.
In multivariable analysis, the age of the general practitioner was associated with increasing odds of prescribing a
not guideline recommended antibiotic therapy.
Conclusions: We found a high degree of guideline conform antibiotic prescriptions in patients with an
uncomplicated urinary tract infection in primary care in Switzerland. However, there is still a substantial use of
fluoroquinolones in empiric therapy.
Keywords: Urinary tract infection, Antibiotic prescribing quality, Primary care, Switzerland, Quality indicator
Background
Antibiotic overuse and inappropriate use are associated
with the emergence of resistant pathogens [1]. The ma-
jority of antibiotics are prescribed in ambulatory care [2]
and urinary tract infections (UTI) are beside respiratory
tract infections one of the most common reasons for
prescribing antibiotics [3]. Many current guidelines (for
example Swiss national guidelines or United States IDSA
guidelines) [4–6] recommend the use of nitrofurantoin,
fosfomycin and trimethoprim -sulfamethoxazol (TMP/
SMX) as empiric first line antimicrobial agents for the
treatment of an uncomplicated UTI (uUTI). TMP/SMX
is recommended when the local resistance patterns of
Escherichia coli (E. coli) are known and the estimated
susceptibility is over 80%. Despite the fact, that the over-
all usage of antibiotics in Switzerland is low compared
to other European countries [7], there is evidence, that
there is a significant amount of inappropriate antibiotic
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prescriptions in UTI [8]. Especially fluoroquinolones
(FC) were still prescribed. Despite their undisputed effi-
cacy in the treatment of UTI, their excessive use in the
last decades resulted in raising resistances not only in
uropathogens, but also in pathogens causing extra-
urogenital infections [5]. Due to their importance in the
treatment in extra-urogenital infections, the use of FC as
an empiric first line antimicrobial agent in uUTI is no
longer recommended [5, 6, 9]. Furthermore, FC use is
associated with further serious adverse effects (for ex-
ample tendinitis and tendon rupture, but also prolonged
QTc, or Clostridium difficile associated diarrhoea) and
both the US Food and Drug Administration and the
European Medicines Agency released warnings and
called for a more restrictive FC use [10, 11].
In this study, we determined the prescribing patterns
and the quality of antibiotic prescribing in ambulatory
UTI and report factors associated with appropriate or
inappropriate antibiotic prescribing.
Methods
We conducted a cross-sectional study between June
2017 and August 2018 in primary care practices in
Switzerland to evaluate resistance patterns as well as
treatment patterns in patients with lower UTI (cystitis).
Details of the study design, as well as recruitment pro-
cedure are reported elsewhere [12]. In this study, lower
UTI was defined as the new onset of typical symptoms
(dysuria, pollakiuria, urgency or haematuria) in combin-
ation with a positive urine dipstick (positive leucocytes).
All UTI in otherwise healthy women without the history
or the clinical suspicion of any functional or anatomical
abnormalities of the urinary tract were considered as un-
complicated. All other conditions as well as UTI in men
were considered as complicated. One hundred sixty-one
Swiss primary care practices as well as two large “walk-
in” practices (larger practices with the following charac-
teristics: longer opening hours, 7 days a week open, of-
fering in-hours continuity of care and out of hours care
for self-referred patients (walk-ins) without having a pre-
vious appointment) participated in the study. In addition
to microbiological work-up, treatment information of
the general practitioners (GP) were obtained. Empirical
treatment of a uUTI with fosfomycin, nitrofurantoin or
TMP/SMX were considered as adequate according to
national guidelines [4]. Although an antibiotic therapy is
recommended, therapeutic approaches with a standby
treatment, delayed prescriptions, and even withholding
antibiotic treatment and symptomatic therapy were rated
as suitable options in uUTI and considered as a guide-
line adherent treatment in all of our calculations [4].
Overall quality of antibiotic prescribing was determined
according to the European Surveillance of Antimicrobial
Consumption (ESAC) disease-specific quality indicators
for outpatient antibiotic prescribing [13].
Statistics
Summary statistics were reported as means (standard
deviation, SD), and number (percentage, %) as appropri-
ate. Antibiotic prescription patterns were compared be-
tween complicated UTI (cUTI) and uUTI using
independent sample Student’s t test and chi-square or
Fisher’s test, as appropriate. Prescription of FC means
prescription of at least one out of ciprofloxacin, levoflox-
acin, moxifloxacin, or norfloxacin. Univariable and mul-
tivariable regression analyses were performed to assess
GP and patient determinants associated with the quality
of antibiotic prescribing. The results of the “walk-in”
clinic were only excluded when analyzing GP character-
istics in univariable and multivariable regression ana-
lyses, due to the fact that different GPs were on duty
and we could not match prescribing patterns with a sin-
gle physician. In 13 patients, final diagnosis (cUTI or
uUTI) was missing; hence, these patients were excluded
for regression analysis, but still included in the overall
analysis. Multilevel logistic models, with GP as first level
clustering variable, were performed for the prescription
of guideline antibiotics or for guideline adherent treat-
ment of uUTI, versus any other antibiotics, and separ-
ately, for the prescription of fluoroquinolone versus
guideline antibiotics. The mixed models with random ef-
fects (GP), were specified as follows: “Antibiotic pre-
scription / treatment ~ Fixed Effects (X) + random
effects of intercept (GP)” where X = GP characteristics:
sex, age, years of experience in practice, type and loca-
tion of practice, work time percentage, affiliation to a
medical network, language (Latin: Italian or French vs.
German speaking); patient characteristics: age, sex, his-
tory of UTI, antibiotic exposure within the last 3
months, inpatient treatment within the last 6 months,
travel history within the last 12 months, reason for the
initial encounter, type of UTI. In univariable analysis,
every fixed effect (X) was considered separately in a sin-
gle model. In multivariable analysis, instead, relevant ef-
fects, that is predictors with P ≤ 0.2 in univariable
analysis, were considered together. Stepwise backward
elimination was used to develop final multivariable
models with best fit for the outcome of interest. Results
of regression analyses were presented as odds ratio (OR)
(95% confidence interval (CI)). ICC was also reported in
multivariable analysis. For all tests, P ≤ 0.05 was consid-
ered statistically significant. According to ESAC [13], we
defined the acceptable ranges of receiving a recom-
mended antimicrobial agent (between 80 and 100%), as
well as the use of a FC antimicrobial agent (< 5%). All
analyses were carried out using statistical package R
(https://www.R-project.org).
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Results
One thousand three hundred fifty-two patients were re-
cruited by 161 GPs and the two large “walk-in” practices.
Basic characteristics of the conducting GPs are described
in Table 1. 1210 (90.4%) patients had a diagnosis of a
uUTI and 129 (9.6%) of a cUTI. 94.9% of the patients
were female and the mean age was 54 years (Table 2).
Antibiotic prescribing patterns
In total 1241 (91.8%) patients were treated with one
antimicrobial agent, 8 patients (0.6%) with two or more
antimicrobial agents. One hundred three patients (7.6%)
did not receive any antibiotic. Of these, 47.6% received
at least one drug for symptomatic therapy, mainly phy-
totherapeutics (n = 34) or analgesic drugs (n = 22).
Regarding the choice of antimicrobial agents, fosfomycin
(44.7%), TMP/SMX (25.8%), and nitrofurantoin (14.5%)
were most often prescribed in uUTI, resulting in a guide-
line conform empiric antibiotic therapy in 84.7%. Includ-
ing patients with standby treatment and no antibiotic
treatment, we found a guideline adherent approach in
85.8% in uUTI. According to the ESAC definitions for
treatment in uUTI, the overall percentage of females re-
ceiving any systemic antibiotic therapy (92.7%) and the
percentage of receiving a recommended antibiotic therapy
(84.7%) were within the desired range. In contrast, the
prescription rate of FC in all uUTI patients (13.8%) was
above the desired range (< 5%), resulting in an evidence-
performance gap of 8.8% (Table 3). The highest amount
of guideline recommended antibiotic prescriptions was
seen in the Geneva region (96.6%), the lowest in the can-
ton of Ticino (64.7%) (Fig. 1 & Supplemental Table 1).
Panel part A shows the relative prescriptions rates of
recommended antimicrobials in female patients with an
uncomplicated urinary tract infection in Switzerland.
Panel part B shows the relative prescriptions rates of
Quinolone prescriptions.
In patients with cUTI 92,3% were treated with antibi-
otics, most often ciprofloxacin (44.5%), TMP/SMX
(15.1%) and fosfomycin (14.3%) were prescribed. Cipro-
floxacin was more often prescribed in cUTI compared to
uUTI (44.5% vs. 6.0%, p = < 0.001). In contrast, fosfo-
mycin and TMP/SMX were more often prescribed in
uUTI (44.7% vs. 14.3%, p < 0.001, and 25.8% vs.
15.1%, p = 0.015, respectively) (Table 2).
Determinants of antibiotic prescribing
Results of uni- and multivariable analyses for guideline rec-
ommended treatments of uUTI are reported in Table 4. In
multivariable analysis, only increasing age of the GP was
significantly associated with reduced odds of prescribing
any guideline recommended antibiotic treatment (OR: 0.96,
p = 0.010) or a guideline adherent treatment (OR: 0.96, p =
0.012).
Including all UTI patients, the diagnosis of a cUTI
(OR: 0.12, p < 0.001) and the sex of the patient (male)
(OR: 0.36, p = 0.048) were additionally identified as sig-
nificant determinants associated with reduced odds of
prescribing fosfomycin, nitrofurantoin or TMP/SMX. In
addition, the age of the GP and the diagnosis of a cUTI
were significant associated with increased odds (OR:
1.04, p = 0.033, and OR: 8.95, p < 0.001, respectively) of
prescribing any FC antibiotic in multivariable analysis.
Particular noteworthy are the relative high intra-cluster
correlation coefficient (ICC) in multivariable analysis
(0.34, and 0.41, respectively) (Supplemental Table 2a).
Differentiating antibiotic prescribing patterns between
patients with a uUTI and cUTI, a female gender of the
GP (OR: 7.08, p = 0.008) in cUTI and increasing age of
Table 1 Basic characteristics of 161 participating General
practitioners
N (%)
Sex
Male 112 (69.6)
Female 49 (30.4)
Age (mean, SD) (missing n = 6) 52.18 (8.83)
Years of experience in ambulatory care
(mean, SD) (missing n = 11)
14.97 (9.56)
Practice type (missing n = 2)
Single practice 42 (26.6)
Double practice 41 (25.9)
Group practice (≥3 GPs/practice) 75 (47.5)
Work-time % of GP (missing n = 3)
30–60% 36 (22.9)
70–80% 39 (24.8)
> 80% 82 (52.2)
Affiliation to a GP network (missing n = 2)
Yes 105 (66.5)
No 53 (33.5)
Language of GP
Latin (Italian / French) 25 (15.5)
German 136 (84.5)
Location of GPa
Central Switzerland 18 (11.0)
Eastern Switzerland 39 (23.9)
Midlands 31 (19.0)
Northwestern Switzerland 30 (18.4)
Lake Geneva region 15 (9.2)
Ticino 5 (3.1)
Zurich 25 (15.3)
Data shown as absolute numbers and in percentage (in parenthesis) if not
stated else. SD: standard deviation; GP: General practitioner
acontains geographical information of the 161 GP practices plus the two
walk-in practices
Plate et al. BMC Family Practice          (2020) 21:125 Page 3 of 9
the GP in uUTI (OR: 1.06, p = 0.003) were associated
with higher odds of prescribing a FC in multivariable
analysis (Supplemental Table 2b). Analysing determi-
nants for each prescribed antibiotic separately showed
results that are more heterogeneous and were provided
in Supplemental Table 2c.
Prescribing no antibiotic
Regarding the patients without any antibiotic treatment,
multivariable regression analysis identified the age of the
GP (OR: 1.04, p = 0.036) and the circumstance, that the
reason for the initial encounter was not the suspicion for
an UTI (OR: 2.97, p = 0.002), as determinants associated
Table 2 Patient characteristics and antibiotic prescription patterns
Total Uncomplicated UTI Complicated UTI P
Patient characteristics
N 1352 1210 129
Sex
M 69 (5.1) 0 (0) 69 (53.5) < 0.001
F 1283 (94.9) 1210 (100) 60 (46.5)
Age (mean, (sd)) 53.75 (20.83) 53.16 (20.88) 58.75 (19.90) 0.004
Antibiotic therapy
No AB 103 (7.6) 88 (7.3) 10 (7.8)
One AB 1241 (91.8) 1116 (92.2) 118 (91.5) 0.921
Two AB 7 (0.5) 5 (0.4) 1 (0.8)
> 2 AB 1 (0.1) 1 (0.1) 0 (0.0)
Antibiotic prescription patterns - Recommended first line antibiotics
Nitrofurantoin 180 (14.4) 163 (14.5) 16 (13.4) 0.855
Fosfomycin 519 (41.6) 501 (44.7) 17 (14.3) < 0.001
TMP / SMX 311 (24.9) 289 (25.8) 18 (15.1) 0.015
Antibiotic prescription patterns - Quinolone antibiotics
Ciprofloxacin 121 (9.7) 67 (6.0) 53 (44.5) < 0.001
Levofloxacin 2 (0.2) 2 (0.2) 0 (0.0) –
Moxifloxacin 3 (0.2) 3 (0.3) 0 (0.0) –
Norfloxacin 93 (7.4) 84 (7.5) 8 (6.7) 0.906
Antibiotic prescription patterns - others
Amoxicillin 14 (1.1) 11 (1.0) 3 (2.5) 0.291
Amoxicillin/Clav 5 (0.4) 4 (0.4) 1 (0.8) 0.975
Cefuroxim 3 (0.2) 2 (0.2) 1 (0.8) 0.677
Other* 6 (0.5) 3 (0.3) 3 (2.5) 0.007
N number of patients; M male; f female; sd standard deviation; AB antimicrobial agent; UTI urinary tract infection; TMP/SMX trimethoprim - sulfamethoxazol; Clav
clavulanic acid
*: This group consist of ceftriaxon (1), azythromicin (1), metronidazol (2), fluconazol (1), and unknown (1)
Table 3 Prescribing performance according to disease specific antibiotic prescribing quality indicators in Europe
Reference No (according to 13) Title Acceptable Range (%) N (%)
3a. Percentage of female patients older than 18 years with
cystitis / other urinary infection (ICPC-2-R: U71) prescribed
antibacterials for systemic use: ATC: J01
80–100 1122 (92.7%)
(ref pop. n = 1210)
3b. receiving the recommended antibacterials: ATC: J01XE or
J01EA or J01XX
80–100 950 (84.7%)
(ref pop. n = 1122)
3c. receiving fluoroquinolones:
ATC: J01M
0–5 155 (13.8%)
(ref pop n = 1122)
N number of patients; ref. pop reference population
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with higher odds for withhold of a recommended anti-
biotic therapy (Supplemental Table 2d).
Discussion
In this study, we determined antibiotic prescribing pat-
terns of general practitioners and factors associated with
antibiotic prescribing in patients with an UTI in primary
care. We found a high adherence to current national and
international guidelines in the empirical therapy in uUTI.
Antibiotic prescribing quality in patients with an UTI
differs throughout the European countries. Whereas
Sweden or the Netherlands reported high rates of anti-
biotic prescriptions according to national guidelines and
a low use of FC (3, and 7.4%, respectively) [14], every
second patient in Hungary was treated with a FC [15].
Recently, Glinz et al. evaluated the quality of antibiotic
prescribing in primary care in Switzerland in a nation-
wide survey for common infectious diseases. They
Fig. 1 Antimicrobial prescribing patterns in Switzerland
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reported inadequate prescribing in 47.3% of all UTI
cases, with a high proportion of FC use (37.2%) [8].
However, these data are biased as they represent a sub-
sample of GPs, which belong to “high prescribers” of a
nationwide interventional study. In our study, 84.7% of
the prescribed antibiotic therapies in uUTI were appro-
priate. Thus, empiric antimicrobial prescribing quality
was within the targeted range of > 80% correct prescrip-
tions according to ESAC. Nevertheless, prescriptions of
FC were still inadequate high and did clearly exceed the
acceptable range of 5% [13]. Increasing age of the GP
and the time in practice were associated with decreased
odds of prescribing a guideline recommended or adher-
ent therapy and with increased odds of prescribing any
FC antibiotic in most of our calculations. As FC were
recommended for a long time [16] many physicians were
used to treat an UTI with FC [17]. However, due to the
high collateral damage, guidelines changed and FC were
no longer recommended. In the treatment of cardiovas-
cular diseases one could show, that the age of the phys-
ician was clearly associated with the knowledge level of
clinical guidelines and younger GPs showed a significant
higher knowledge of the current guidelines [18]. Al-
though comparative data for the treatment of UTI are
missing, the assumption, that some GPs treat UTIs “as
always” seem to be feasible and could explain, at least in
part, our finding. However, due to the still favourable re-
sistance patterns of uropathogenic E.coli in Swiss pri-
mary care [4, 12], there is no obvious need for the use of
FC in the empirical therapy of uUTI. The still high evi-
dence - performance gap of 8.8% in prescribing FC anti-
biotics, should be addressed by specific interventions.
One have to keep in mind, that antibiotic prescriptions
are a complex process influenced by many factors (for
example personality characteristics, or the interpersonal
relation within the patient-GP encounter, as well as ex-
ternal factors like public campaigns and characteristics
of the national health care system) [19–22], and previous
national studies using health claims data or selective inter-
ventions showed no or only limited effects on appropriate
prescribing [23, 24]. This highlights the need for multifa-
ceted interventions affecting GPs prescribing decisions as
changing prescribing behavior seems possible [25]. A con-
tinuous postgraduate education consisting of the provision
of Up-to-date clinical guidelines and communication skills
training are essential, but need to be embedded in further
interventions, for example selective antimicrobial resist-
ance reporting [26, 27], and patient education campaigns.
In contrast to uUTI there is no common consensus on
the definition of cUTI [28]. A variety of underlying dis-
eases or host conditions are known to be a risk factor
for a cUTI [6] and hence no guidelines with an universal
approach to this patient group exist and treatment rec-
ommendations, especially for men, differ within the
available guidelines [4, 6, 29]. Reports, that for example
cUTI in men can be uncomplicated illustrate, that an in-
dividual approach, dependent of the underlying disease
and local resistance rates, might be necessary [6, 28, 30].
Due to the heterogeneity and the selective lack of guide-
lines, it is difficult to rate the appropriateness of anti-
biotic prescribing in this group. We found that the
diagnosis of a cUTI or a male gender of the patient were
significantly associated with increased odds of prescrib-
ing a FC or decreased odds of prescribing antibiotics
recommended for uUTI. However, in men it is believed,
that an isolated infection of the bladder without an in-
fection of the prostate is rare, so prostate uptake of the
antimicrobial agent is an important issue. The common
practice, beginning an empiric therapy with an intraven-
ous therapy (for example with a third generation ceph-
alosporin) and switching to an oral agent with a good
bioavailability when antimicrobial resistance patterns are
available, is not feasible in most cases in primary care,
especially if disease severity favours an outpatient treat-
ment with only an oral antimicrobial agent. This point
up the importance of a urine culture in cUTI, as the em-
pirical therapy with a FC or TMP/SMX (as both show a
good prostate penetration) can be adjusted in case of re-
sistant pathogens. Furthermore, it highlights the need for
further research in this field, as current guidelines did not
cover well this common issue in ambulatory care.
It is worth mentioning, that we observed in all of our
calculations a major ICC. Thus, a quite large amount of
variation in prescribing patterns in the individual GP
must be due to additional (unmeasured) GP, practice, or
patient characteristics. Patient and/or GP preferences,
prior microbial results, patient allergies, (local) guide-
lines, or even missing guidelines in the case of cUTI,
might be possible factors.
A significant proportion of the patients was not
treated with any antimicrobial agent. The use of anti-
inflammatory and/or analgesic drugs [31, 32], or to
postpone the use of antibiotics could be another reli-
able option in selected patients [33]. A recent study
reported that two thirds of women seeking care for
an UTI episode are willing to postpone antibiotics.
Moreover, half of the women waited a couple of days
before seeking care in respect to the benign cause of
most uUTI episodes [33]. In contrast, Gharbi et al.
showed in a recent study, that elderly patients with
no or delayed antibiotic prescriptions for UTI are at
a significant higher risk for bloodstream infections
[34]. Thus, these approaches should be avoided in
this patient group. Taken together, treatment options
other than immediate antibiotic prescriptions can be
a feasible alternative and should be taken into ac-
count in ambulatory care and antibiotic stewardship
programs.
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This study has some limitations. First, we are unaware
of the reason regarding the choice of antimicrobial ther-
apy. The personal history of a resistant microorganism,
or an allergy or intolerance to a first line antibiotic are
potential reasons for the use of an alternative antimicro-
bial agent. However, although it is unlikely that these
factors make a treatment with any of the first line antibi-
otics impossible, we cannot rule out, that the choice of
another antimicrobial agent than the first line antibiotics
was the correct clinical approach in some cases. Second,
we are unaware of coexisting complaints of the patients
at the time of encounter. Although rare, a second infec-
tion, which need an antibiotic coverage, could influence
the GPs decision of the antibiotic regime towards a FC.
Conclusions
We could show that there is a very high degree of guide-
line recommended antibiotic use in the empiric therapy
of uUTI in primary care in Switzerland. However, the
use of FC in the empirical therapy of uUTI is still inad-
equate high and should consequently be addressed by
multifaceted interventions.
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